Study of BHV-1400 in IgA Nephropathy

Trial statusRecruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age18-65

SponsorBiohaven Therapeutics Ltd.

About this trial

The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).

None

Any secondary IgAN

Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause

20 Participants

are divided into 1 treatment group

Locations15

Select a site below to view it on the map.

United Kingdom

United States

Connecticut

Florida

Georgia

Illinois

Indiana

Michigan

Missouri

South Dakota

Texas

Utah

Biohaven Therapeutics Ltd.

Lead sponsor